ARGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Argenx (ARGX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock demonstrates strong growth potential, supported by robust financial performance, positive clinical trial results, and bullish analyst ratings. Despite recent price declines, the company's fundamentals and upward trajectory in sales and earnings make it a compelling long-term investment.
The stock's MACD is negative and expanding, indicating bearish momentum. RSI is at 20.935, suggesting oversold conditions. The stock is trading near its S1 support level of 777.796, with resistance at 813.643. The moving averages are converging, indicating potential consolidation.
Strong Q4 2025 revenue growth of 74.12% YoY, reaching $1.29B.
Vyvgart's annual sales of $4.2B and positive Phase 3 ADAPT OCULUS results.
FDA priority review for label expansion of Vyvgart.
Analysts have raised price targets and maintain bullish ratings, with targets as high as $1,
First year of profitability in 2025 with $4.2B in global product net sales.
Recent price decline of -5.56% in regular market trading and -3.10% in pre-market.
Net income and EPS dropped YoY in Q4 2025, reflecting margin pressures.
Gross margin slightly declined by 2% YoY.
In Q4 2025, revenue increased by 74.12% YoY to $1.29B, driven by strong Vyvgart sales. However, net income dropped by 31.16% YoY to $532.95M, and EPS fell by 30.98% to $8.02. Gross margin decreased slightly to 88.36%. Despite the decline in profitability metrics, the company achieved its first year of profitability in 2025 with $4.2B in global product net sales.
Analysts remain bullish on Argenx, with multiple firms raising price targets. The highest target is $1,317 (Wells Fargo), reflecting confidence in the company's growth trajectory. Analysts highlight strong Vyvgart sales momentum and a robust pipeline. One downgrade (Baird) cited valuation concerns, but the majority maintain buy or overweight ratings.
